Genistein-mediated inhibition of IGF-1 (usually upregulated in prostate cancer bone metastasis) also silences the β-catenin pathway (Rubin et al., 2004[112]; Mahmoud et al., 2014[86]). The gene discussed is IGF1; the disease is prostate carcinoma.